Table 2.

Standardized incidence ratios for thyroid cancer in transplant recipients

	Cases	SIR (95%CI)
Overall	356	2.50 (2.25–2.77)
Sex
Male	150	2.77 (2.35–3.25)
Female	206	2.33 (2.02–2.67)
Race/ethnicity
White, non-Hispanic	231	2.38 (2.08–2.71)
Black, non-Hispanic	38	2.69 (1.90–3.69)
Hispanic	59	2.76 (2.10–3.55)
Asian/Pacific Islander	28	2.84 (1.89–4.10)
Age at transplantation, years
0–19	11	6.14 (3.07–10.99)
20–34	48	2.96 (2.18–3.92)
35–49	133	2.75 (2.30–3.26)
50–64	142	2.28 (1.92–2.68)
65+	22	1.61 (1.01–2.43)
Year of transplantation
1987–1994	75	3.08 (2.42–3.86)
1995–1999	100	2.53 (2.06–3.08)
2000–2004	104	2.24 (1.83–2.71)
2005–2012	77	2.40 (1.89–3.00)
Time since transplantation, years
0.0–0.4	47	4.31 (3.17–5.74)
0.5–0.9	42	4.10 (2.96–5.54)
1.0–1.9	50	2.67 (1.98–3.52)
2.0–4.9	81	1.83 (1.45–2.27)
5.0–9.9	93	2.29 (1.85–2.81)
10.0+	43	2.43 (1.76–3.27)
Transplanted organ
Kidney	237	2.87 (2.52–3.26)
Liver	53	1.63 (1.22–2.13)
Heart	34	2.39 (1.65–3.34)
Lung	13	2.34 (1.25–4.00)
Other or multiple	19	2.49 (1.50–3.89)
Thyroid cancer histology
Papillary	323	2.68 (2.39–2.99)
Follicular	17	1.21 (0.70–1.93)
Medullary	6	1.75 (0.64–3.82)
Anaplastic	3	1.85 (0.38–5.41)
Other/unspecifieda	7	2.60 (1.04–5.35)
Thyroid cancer stage at diagnosis
Local	241	2.53 (2.22–2.87)
Regional	91	2.65 (2.13–3.25)
Distant	8	1.03 (0.45–2.03)
Unstaged	16	3.31 (1.89–5.37)

Abbreviations: SIR, standardized incidence ratio; CI, confidence interval.

^aThis category includes 3 cases of unspecified carcinoma (International Classification of Diseases for Oncology version 3 morphology code 8010), 1 mixed adenocarcinoma (8255), 1 papillotubular adenocarcinoma (8263), 1 insular carcinoma (8337), and 1 mucoepidermoid carcinoma (8430).